麻豆AV出品在线观看_偷偷鲁视频成人免费视频_乱子伦在线观看中文字幕_人碰人摸人爱免费视频在线观看

Search for the keyword:
   
What is Apixaban?
source:Vitalpharms Company Ltd.    Release date:2021-8-30 13:52:57
Apixaban (ELIQUIS) is an oral selective activation factor X inhibitor, jointly developed by Pfizer and Bristol-Myers Squibb. Eliquis can prevent thrombosis, but the adverse effects of bleeding are lower than that of the old drug warfarin. It is used for thrombosis prevention in patients who have undergone hip or knee replacement surgery.

Apixaban is a new type of oral anticoagulant, a new type of oral factor Xa inhibitor, and a drug used to prevent and treat blood clots. The recommended dose is 2.5 mg, taken orally twice a day, which can effectively prevent venous thromboembolism without increasing the risk of bleeding. There is no need for routine monitoring of coagulation function and no dose adjustment. Suitable for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE)
Previous:Basic introduction of dabigatran etexilate/
Next:The role and efficacy of rivaroxaban tablets

About Us
Company Profile
Culture
Qualification
Staff style
Organization
News
Company News
Industry news
Media coverage
Products
Agent Products
Intermediates
Associated with the review and intermediates
Animal health related products
Merchants joined
Industry Standard
Quality certification
Contact Us
Vitalpharms Company Ltd.
Add.: 2/F, 3# Buliding, 169 Shihua Rd. West, Zhuhai, Guangdong, China.
Tel: +86-756-3326819/ 3221531
Fax: +86-756-3326816
E-MAIL: sales@www.palmbeachunited.com
Copyright©Vitalpharms Company Ltd.  Internet Drug Information Service Qualification Certificate: (Guangdong)- Non-operational -2023-0028   粵ICP備10097759號(hào)